[The use of amantadine sulfate in combined therapy of Parkinson's disease].
The efficacy of PK-Merz medication has been studied in 17 patients with Parkinson's disease (PD), who have developed a resistance to levodopa as a result of a long-term treatment. The efficacy was evaluated according to clinical symptoms (UPDRS) and electromyography (EMG) indices. The summary motor score measured by UPDRS estimated as 49-79 (58.1 +/- 3.2) one hour after a single levodopa/carbidopa intake, decreased to 36-65 (45.2 +/- 2.9, p < 0.05) after levodopa/carbidopa combination with i.v. PK-Merz infusion. The biceps and triceps resting EMG amplitude and values of its variance also decreased significantly (p < 0.01). The percentage of the registered burst muscle discharges of 4-7 Hz frequency reduced from 32 to 13%. Under functional stress, the reflex antagonist muscle co-activation decreased in the majority of the patients. Selective correlations were found between the EMG indices and some UPDRS PD symptom scores. PK-Merz improves both motor functions and muscle coordination in PD.
Karaban'
I N
IN
Lukhanina
E P
EP
Kapustina
M T
MT
Karasevich
N V
NV
D000368:Aged; D000547:Amantadine / Q000008:administration & dosage / Q000627:therapeutic use*; D002230:Carbidopa / Q000627:therapeutic use; D015259:Dopamine Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004576:Electromyography; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*
D015259:Dopamine Agents; D004338:Drug Combinations; C009265:carbidopa, levodopa drug combination; D007980:Levodopa; D000547:Amantadine; D002230:Carbidopa